Hep C patients claim Bristol-Myers rushed into trial

Did Bristol-Myers Squibb ($BMY) rush an experimental hepatitis C drug trial, despite signs that the treatment could be toxic? Some patients who suffered injury during the study say so--and they're suing the drugmaker for damages. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.